Alumis Just Got Cut in Half — but Wall Street Knee-Jerked the Wrong Program

Alumis (ALMS) lost more than half its value in a single September day, and the mainstream read is that it deserved it. On September 1 the stock fell 56% to $9.50 from $21.81, wiping out roughly $1.6 billion of market value in about 25 million shares. The trigger, real and serious: a Phase 2b trial of its drug envudeucitinib in systemic lupus failed its primary and secondary endpoints in the overall patient population. But the number the market latched onto is not the number that decides what this company is worth in the next twelve months. The program that actually pays the bills — plaque psoriasis, with a regulatory filing on track for the fourth quarter — did not fail at all.

The reason this matters right now is timing. Beginning September 8, management walks into four investor conferences in eight days. It is the company's first public stage since the crash, and it is a chance to do exactly what the selloff did not: separate the lupus setback from the psoriasis economics.

The failure that was partly a population problem

The lupus trial, called LUMUS, enrolled 408 patients with moderately-to-severely active, autoantibody-positive systemic lupus and gave them one of three doses of envudeucitinib or placebo over 48 weeks. In the group as a whole, the drug missed its primary composite endpoint (BICLA, a standard measure of overall disease activity) and its key secondary measures of response and skin improvement.

Here is where the "story" and the "mechanics" split. Lupus patients are not one population for this class of drug. Envudeucitinib works by blocking TYK2, an enzyme that sits on the Type I interferon pathway — the immune signal that drives a large share of severe lupus. Alumis pre-specified a subgroup of patients with a "high interferon gene signature" (IFNGS-high), who carry the genetic fingerprint of a disease driven by that exact pathway. In that group — which the company says represents the majority of moderate-to-severe lupus cases — the drug produced robust responses on the same primary and secondary endpoints. The catch: those patients were unexpectedly under-represented in the trial, which diluted the overall readout.

Management is all-in on that read. Chief Medical Officer Jörn Drappa called the subgroup effect "highly compelling" in a disease with no targeted oral therapy, and Alumis says it will take the data to regulators to discuss a Phase 3 lupus program aimed specifically at that subgroup.

Read that as a claim to test, not a fact to bank. The company has not yet released the actual response-rate numbers behind the subgroup claim, only the qualitative picture. "Highly compelling" is an adjective, and the whole lupus option now rests on whether the IFNGS-high signal survives a properly enriched, properly powered trial — plus on an FDA willing to design around a subgroup after the overall study missed. That is a year-plus of uncertainty, at best.

The program that did not break

Now the part the selloff buried. Alumis's most advanced and most valuable program is envudeucitinib in moderate-to-severe plaque psoriasis, a market that touches over 8 million U.S. adults. Its Phase 3 ONWARD trials met all primary and secondary endpoints, and the efficacy claims are the kind that get this stock its premium when they work: around 65% of patients reached PASI 90 (near-total clearance) and more than 40% reached PASI 100 (complete clearance) at week 24, with long-term data showing 54% of patients at complete clearance by week 48. The company calls it the leading skin clearance among next-generation oral psoriasis therapies, and it has positioned a New Drug Application to the FDA for the fourth quarter of 2026 — a filing it reaffirmed even while announcing the lupus miss.

That NDA is the near-term value driver, and it is what the post-crash price does not credit. At a roughly $1.4 billion market cap and around a $0.9 billion enterprise value, with no revenue yet, ALMS is being valued as if the psoriasis approval is unlikely. That is the divergence Wells Fargo flagged the day of the crash: the bank cut its price target from $51 to $25 but kept an Overweight rating, arguing the drop "seems overdone" and that the market is assigning little credit to what it calls a high-chance psoriasis approval. Baird trimmed its target from $35 to $27 while keeping Outperform.

The honest pushback is competitive. Envudeucitinib would not enter an empty field — Bristol Myers Squibb's Sotyktu is the only approved oral TYK2 inhibitor today, and a competing drug (zasocitinib) just showed superiority to Sotyktu in a head-to-head Phase 3. The oral TYK2 class is crowding, and psoriasis is a huge but contested market. "Best-in-class in a hot class" is a claim that has to be defended through launch, not just at an FDA filing.

What the conferences are really for

The four appearances — Wells Fargo on September 8, Cantor on September 9, Morgan Stanley on September 14, and Baird on September 15 — are not themselves catalysts. Fireside chats and a presentation do not move a clinical timeline. They matter for one reason: they are the first venue where Alumis must rebuild the story the crash tore down.

Listen for two things. First, whether management keeps the Q4 psoriasis NDA at the center of every answer, since that is the event that can actually re-rate the stock. Second, whether they frame the lupus Phase 3 path in numbers rather than adjectives. The credibility bar is the pattern the persona always checks: management has now under-delivered on one big clinical readout, so "highly compelling" earns trust only when it arrives with response rates and a trial design that is sized to the enriched subgroup from day one.

The balance sheet makes waiting affordable. Alumis held $502 million in cash and marketable securities at the end of the second quarter, enough to fund operations into the fourth quarter of 2027 — past the NDA filing, the FDA review window, and comfortably into a potential launch.

This is not a GARP story and it is not a "cheap fallen biotech" entry either. There is no earnings multiple to anchor; this is a binary clinical and commercial story, and the near-term variable is one event: the Q4 NDA filing, and whether the market lets the psoriasis math carry a $1.4 billion valuation again. The conferences won't decide that. They will show whether Alumis can get its own story off the lupus mat and back onto the psoriasis one — which, after a 56% panic, is the only re-rating step it controls this month.